-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 22, Odonate announced the termination of the development of tesetaxel and the termination of the company's operations.
Odonate said that, based on the FDA's feedback at the pre-NDA meeting, the clinical data of teseltaxel is unlikely to support the FDA's approval of the product.
Tesitetaxel belongs to the taxane class of anticancer drugs.
As a new type of taxane compound, tesitetaxel has unique characteristics: (1) it will not be excreted by P-glycoprotein, (2) has higher oral bioavailability, (3) has high Water solubility; (4) has a longer half-life (take the drug once every 3 weeks).
In August 2020, Odonate announced the positive top-line results of the Phase III (CONTESSA) study of Teselstat for the treatment of patients with HR+/Her2- metastatic breast cancer.
However, the publication of the research data caused Odonate's stock price to plummet by 45%, because investors believe that the therapy has safety issues.
